We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Excellium Form 483 Says Company Should Investigate Discrepancies
Excellium Form 483 Says Company Should Investigate Discrepancies
April 5, 2010
Excellium Pharmaceutical did not investigate an anomaly during content uniformity testing of anxiety drug chlordiazepoxide HCl and clidinium bromide capsules — and
approved and released the batch.